Vor Biopharma Inc. (VOR) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Vor Biopharma Inc.

    NASDAQ: VOR · Real-Time Price · USD
    33.62
    -0.19 (-0.56%)
    At close: Sep 26, 2025, 3:59 PM
    33.00
    -1.84%
    After-hours: Sep 26, 2025, 06:46 PM EDT

    Vor Biopharma Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a n/a n/a n/a
    Cost of Revenue
    		 3.53M 3.49M 8.96M 4.45M
    Gross Profit
    		 -3.53M -3.49M -8.96M -4.45M
    Operating Income
    		 -121.19M -126.04M -93.42M -69.02M
    Interest Income
    		 4.27M 8.17M 1.32M 119K
    Pretax Income
    		 -116.91M -117.86M -92.09M -68.9M
    Net Income
    		 -116.91M -117.86M -90.77M -68.78M
    Selling & General & Admin
    		 27.88M 31.72M 28.87M 21.49M
    Research & Development
    		 93.31M 94.31M 64.55M 47.53M
    Other Expenses
    		 -3.53M -3.49M n/a n/a
    Operating Expenses
    		 117.66M 122.54M 93.42M 69.02M
    Interest Expense
    		 n/a n/a n/a n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 -121.19M 126.04M 93.42M 69.02M
    Income Tax Expense
    		 n/a n/a -1.32M -119K
    Shares Outstanding (Basic)
    		 3.44M 3.36M 1.98M 1.86M
    Shares Outstanding (Diluted)
    		 3.44M 3.36M 1.98M 1.86M
    EPS (Basic)
    		 -34 -35 -46.6 -37.8
    EPS (Diluted)
    		 -34 -35 -46.6 -37.8
    EBITDA
    		 -113.39M -114.37M -90.89M -67.58M
    EBIT
    		 -116.91M -117.86M -92.09M -68.9M
    Depreciation & Amortization
    		 3.53M 3.49M 2.52M 1.43M

    Add to Watchlist